INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 429m ago
HOUSE PTR29m ago
SEC 13F29m ago
ROBINHOOD CHAIN29m ago
SEC FORM 4/Grant or awardVerified data

Bohen Sean reported OLMA

Director, PRESIDENT AND CEO · Olema Pharmaceuticals, Inc. · Olema Pharmaceuticals, Inc. — Stock Option (Right to Buy)

Side
A
Value
—
Shares
850.0K
Price
—
Executed
Feb 2, 2026
Disclosed
Feb 4, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Feb 2 executedFeb 4, 2026 disclosed

OLMA · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · OLMA

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    OJ
    O'Byrne JasonCHIEF FINANCIAL OFFICER
    OLMAOlema Pharmaceuticals, Inc.
    Grant or award
    		A—
    650.0K sh
    		Sep 1, 2026Sep 2, 2026
    traded Sep 1, 2026
    		+1dSEC FORM 4

    Evidence

    15
    HG
    Hrustanovic GorjanDirector
    OLMAOlema Pharmaceuticals, Inc.
    Grant or award
    		A—
    29.5K sh
    		Jun 18, 2026Jun 23, 2026
    traded Jun 18, 2026
    		+5dSEC FORM 4

    Evidence

    11
    HC
    Harmon CyrusDirector
    OLMAOlema Pharmaceuticals, Inc.
    Grant or award
    		A—
    29.5K sh
    		Jun 18, 2026Jun 23, 2026
    traded Jun 18, 2026
    		+5dSEC FORM 4

    Evidence

    15
    RP
    Raman PrakashDirector
    OLMAOlema Pharmaceuticals, Inc.
    Grant or award
    		A—
    29.5K sh
    		Jun 18, 2026Jun 23, 2026
    traded Jun 18, 2026
    		+5dSEC FORM 4

    Evidence

    9
    RP
    Raman PrakashDirector
    OLMAOlema Pharmaceuticals, Inc.
    Grant or award
    		A—
    2,911 sh
    		Apr 28, 2026Apr 29, 2026
    traded Apr 28, 2026
    		+1dSEC FORM 4

    Evidence

    9
    RP
    Raman PrakashDirector
    OLMAOlema Pharmaceuticals, Inc.
    Grant or award
    		A—
    24.1K sh
    		Apr 28, 2026Apr 29, 2026
    traded Apr 28, 2026
    		+1dSEC FORM 4

    Evidence

    19
    AL
    Austin Sasha LuVP of Finance and Controller
    OLMAOlema Pharmaceuticals, Inc.
    Grant or award
    		A—
    29.3K sh
    		Feb 2, 2026Feb 17, 2026
    traded Feb 2, 2026
    		+15dSEC FORM 4

    Evidence

    31
    AL
    Austin Sasha LuVP of Finance and Controller
    OLMAOlema Pharmaceuticals, Inc.
    Grant or award
    		A—
    11.7K sh
    		Feb 2, 2026Feb 17, 2026
    traded Feb 2, 2026
    		+15dSEC FORM 4

    Evidence

    5
    ZN
    Zojwalla NaseemCHIEF MEDICAL OFFICER
    OLMAOlema Pharmaceuticals, Inc.
    Grant or award
    		A—
    250.0K sh
    		Feb 2, 2026Feb 4, 2026
    traded Feb 2, 2026
    		+2dSEC FORM 4

    Evidence

    2
    MC
    Myles David C.CH. DISCOV. & NON-CLIN DEV OFF
    OLMAOlema Pharmaceuticals, Inc.
    Grant or award
    		A—
    106.3K sh
    		Feb 2, 2026Feb 4, 2026
    traded Feb 2, 2026
    		+2dSEC FORM 4

    Evidence

    5
    ZN
    Zojwalla NaseemCHIEF MEDICAL OFFICER
    OLMAOlema Pharmaceuticals, Inc.
    Grant or award
    		A—
    106.3K sh
    		Feb 2, 2026Feb 4, 2026
    traded Feb 2, 2026
    		+2dSEC FORM 4

    Evidence

    9
    BS
    Bohen SeanDirector, PRESIDENT AND CEO
    OLMAOlema Pharmaceuticals, Inc.
    Grant or award
    		A—
    275.0K sh
    		Feb 2, 2026Feb 4, 2026
    traded Feb 2, 2026
    		+2dSEC FORM 4

    Evidence

    2
    MC
    Myles David C.CH. DISCOV. & NON-CLIN DEV OFF
    OLMAOlema Pharmaceuticals, Inc.
    Grant or award
    		A—
    250.0K sh
    		Feb 2, 2026Feb 4, 2026
    traded Feb 2, 2026
    		+2dSEC FORM 4

    Evidence

    33
    HC
    Harmon CyrusDirector
    OLMAOlema Pharmaceuticals, Inc.
    Open-market sale
    		SELL$269K
    10.0K sh
    		Jan 20, 2026Jan 21, 2026
    traded Jan 20, 2026
    		+1dSEC FORM 4

    Evidence

    30
    HC
    Harmon CyrusDirector
    OLMAOlema Pharmaceuticals, Inc.
    Open-market sale
    		SELL$102K
    3,489 sh
    		Jan 14, 2026Jan 16, 2026
    traded Jan 14, 2026
    		+2dSEC FORM 4

    Evidence

    34
    KC
    Kovacs Shane William CharlesCH. OPERATING & FINANCIAL OFF.
    OLMAOlema Pharmaceuticals, Inc.
    Open-market sale
    		SELL$107K
    3,822 sh
    		Jan 13, 2026Jan 15, 2026
    traded Jan 13, 2026
    		+2dSEC FORM 4

    Evidence

    44
    KC
    Kovacs Shane William CharlesCH. OPERATING & FINANCIAL OFF.
    OLMAOlema Pharmaceuticals, Inc.
    Open-market sale
    		SELL$2.87M
    100.0K sh
    		Jan 15, 2026Jan 15, 2026
    traded Jan 15, 2026
    		+0dSEC FORM 4

    Evidence

    30
    MC
    Myles David C.CH. DISCOV. & NON-CLIN DEV OFF
    OLMAOlema Pharmaceuticals, Inc.
    Open-market sale
    		SELL$429K
    15.0K sh
    		Jan 14, 2026Jan 14, 2026
    traded Jan 14, 2026
    		+0dSEC FORM 4

    Evidence

    37
    MC
    Myles David C.CH. DISCOV. & NON-CLIN DEV OFF
    OLMAOlema Pharmaceuticals, Inc.
    Open-market sale
    		SELL$283K
    10.0K sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    12
    MC
    Myles David C.CH. DISCOV. & NON-CLIN DEV OFF
    OLMAOlema Pharmaceuticals, Inc.
    Option exercise
    		M$244K
    50.0K sh
    		Jan 13, 2026Jan 14, 2026
    traded Jan 13, 2026
    		+1dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001831218-26-000002
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Feb 2, 2026
    Published
    Feb 4, 2026
    Ingested by INSIDER
    Nov 5, 04:19 UTC
    Last re-read
    Nov 5, 04:19 UTC

    Extracted facts

    Filer
    Bohen Sean
    Role
    Director, PRESIDENT AND CEO
    Transaction
    Grant or awardAs filed: “A”
    Asset
    Olema Pharmaceuticals, Inc. — Stock Option (Right to Buy)
    Ticker
    OLMA
    Shares
    850.0K
    Price per share
    $0
    Execution date (reported)
    Feb 2, 2026
    Owned after transaction
    850.0K shares
    Days from execution to publication
    2

    What this establishes

    Bohen Sean filed this Form 4 reporting a grant or award of OLMA on Feb 2, 2026. It became public on Feb 4, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director, PRESIDENT AND CEO
    Bohen Seancik:0001831218
    Issuer
    Olema Pharmaceuticals, Inc.cik:0001750284

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.